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ABSTRACT 
Many patients with chronic pain complain of sleep problems. However, the 
relationship between sleep and pain in these patients is still not fully understood. 
Experimental models are used to understand the interaction between pain and 
sleep, but up until now all such models have been of short duration and assessed 
different end-points of sleep disruption. The aim of the study is to develop a 
longer-acting model to mimic the muscle pain seen in patients with chronic pain, 
assess whether the end-point of sleep disruption is constant over subjects and 
assess whether the disruption is dependent on length of stimulation and/or the 
sleep stage involved. Twelve healthy male subjects participated in the study. They 
were exposed to multiple hypertonic and isotonic saline infusions, for a duration 
of ten minutes, both while awake and during all stages of sleep. The muscle pain 
intensity and quality during wakefulness were assessed using the Visual Analogue 
Scale (VAS) and McGill Pain Questionnaire. Polysomnographic signals were 
recorded to score sleep changes during all sleep stages. During wakefulness 
hypertonic saline infusions produce significantly greater VAS Scores than 
isotonic saline infusions. Differences between the VAS scores from evening to 
morning were non-significant, therefore implying that there was no overnight 
hyperalgesia after any of the experimental stimulations. When compared to the 
isotonic saline infusions, the noxious hypertonic saline infusions triggered 
significantly more microarousals during REM (67% of subjects); more sleep stage 
shifts in SWS (42% of subjects) and more full arousals during stage 2 (83% of 
subjects), SWS (67% of subjects) and REM (67% of subjects) sleep. The data 
suggests that pain during sleep triggers multiple different end-points of sleep 
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disruption during sleep and the specific end-points may be determined by the 
sleep stage involved. The sleep disturbances found in our model of experimental 
pain may be similar to those found in patients with chronic muscle pain. 
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1.1   Introduction 
Pain, by definition, is an unpleasant sensory and emotional experience associated 
with actual or potential tissue damage, or described in terms of such damage 
(Merskey and Bogduk 1994). In other words, pain is not only described as being 
noxious, but rather it is also an emotional experience. Pain is so important to 
survival that it’s processing in the brain does not occur in one distinct area 
(Ranney 1996). Pain affects multiple areas and pathways in the brain, such as the 
brainstem, cortical areas and limbic system (Nofzinger and Derbyshire 2007). 
Emotion is permanently involved in all pain because the limbic system, which 
influences and creates emotion, is always affected in pain. Hence, pain is a 
subjective phenomenon – the same painful stimulus experienced can be 
interpreted and expressed in many ways by different people.  
 
Pain, whether acute or chronic, can also be classified according to the location of 
the pain, the organ system affected, the cause of the pain and how long the pain 
has persisted (Sessle 2007). In this literature review I will be concentrating on 
musculoskeletal pain. The increasing prevalence of musculoskeletal pain has been 
described as an epidemic and insight is needed to understand the condition (Main 
and Williams 2007).  
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1.2   Musculoskeletal pain 
Musculoskeletal pain is a common complaint among patients with chronic pain 
and originates in skeletal muscle, tendons and surrounding fascia (Mense 1993). 
Acute pain exists as a protective measure to warn against damage, whereas some 
types of chronic pain serves no known function and becomes a disease which 
affects many aspects of the lives of patients that experience or live with chronic 
pain (Sessle 2007). A literature review on the prevalence of pain conducted in 
2002 revealed the prevalence rates of chronic muscle pain varying from 11.5% to 
55.2% (Ospina and Harstall 2002). 
 
Despite extensive research done in the field of musculoskeletal pain, chronic 
myalgia (muscle pain) remains a problem due to the lack of knowledge of the 
prevention and treatment of peripheral and more so the central sensitisation 
observed in patients with chronic muscle pain (Arendt-Nielsen and Svensson 
2001). 
 
Musculoskeletal pain is often characterized by the local and referred pain as well 
as hyperalgesia (Graven-Nielsen et al. 2002). The local muscle pain is the area of 
muscle where the nociceptors are activated, while the referred pain occurs in an 
area discontinuous or away from the local pain area (Graven-Nielsen et al. 
1997b).  An example of referred pain is the model of tibialis anterior direct pain 
and referred pain, where hypertonic saline injected into the muscle induces a pain 
in the anteromedial aspect of the ankle (see figure 1) (Travell and Simons 1993). 
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The referral patterns from the muscles stimulated are characteristic of that muscle 
and are fairly consistent and reproducible (Travell and Simons 1993) 
Hyperalgesia is defined as the increased sensitivity to a normally noxious stimulus 
that an organism may experience after inflammation, injury, or other 
physiological change that lowers the threshold to pain (Kehl and Fairbanks 2003). 
 
 
 
Pain is complex and subjective, and therefore becomes very difficult to assess 
objectively. When assessing muscle pain, it is preferred that the tests are 
multimodal and are able to evaluate both the intensity and type of pain (Graven-
Nielsen and Arendt-Nielsen 2003). Multimodal assessments on pain result in a 
more conclusive and thorough result as opposed to a single input assessment 
which would generate a very limited part of pain perception. Questionnaires using 
numeric scales and words as descriptors are typically used to assess pain in adults 
Figure 1. The distribution of local and referred muscle 
                 pain after stimulation of the anterior tibilais 
                 muscle. 
                 (Arendt-Nielsen and Svensson 2001) 
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(Lavigne et al. 2007). A Visual Analogue Scale (VAS) is a numeric scale which 
consists of a  0 - 100mm line where  0mm indicates “no pain” and 100mm 
indicates “worst pain ever felt” (see Figure 2). The McGill Pain Questionnaire 
(MPQ) consists primarily of three major classes of word descriptors: sensory; 
affective; and evaluative (Melzack 1975). The sensory words describe the sensory 
qualities of the experience, the affective words describe the tension and fear that 
are part of the painful experience, and the evaluative words describe the subjective 
overall intensity of the total pain experience (Melzack 1975). 
 
 
   0mm                                                                         100 mm 
No pain                                                            Worst pain ever felt 
 
Figure 2. The Visual Analogue Scale for measurement of pain 
 
1.2.1   Mechanisms of musculoskeletal pain 
The sensation of local muscle pain is a result of the activation of group III and 
group IV muscle nociceptors (Mense 2003). Group III afferents are thin 
myelinated fibres with conduction velocities between 2.5 and 30 m/s, while group 
IV affrents are unmyelinated and have conduction velocities less than 2.5 m/s 
(Mense and Simons 2001). The muscle nociceptors are free-nerve endings and it 
is here where the neuropeptides are synthesized and are released when there is 
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stimulation of the receptor (Graven-Nielsen and Mense 2001). The nociceptors 
then generate an electrical impulse to the dorsal horn in the spinal cord via the 
group III and IV fibres, where it gets transmitted to the brain where the pain is 
perceived (Ranney 1992; Graven-Nielsen and Arendt-Nielsen 2007).  
 
When a muscle is pathologically altered, there is a peripheral release of 
neuropeptides which increases nociceptor activity – this is referred to as 
peripheral sensitisation (Ranney 1992, Mense 2003). It is this peripheral 
sensitization that causes the effects of hyperalgesia (Graven-Nielsen and Mense 
2001). Although peripheral mechanisms are mainly responsible for hyperalgesia, 
evidence also shows that central sensitization, in part, mediates hyperalgesia. 
 
Sensitisation of the dorsal horn is referred to as central sensitisation, which is one 
of the first steps in the shift from acute to chronic muscle pain (Ranney 1992). 
Central sensitisation may also be involved in referred pain (Arendt-Nielsen et al. 
1998). The mechanisms behind the processes of referred pain are still not clearly 
understood although according to Feinstein et al. (1954) as cited by Arendt-
Nielsen et al. (1998), it seems that central mechanisms probably generate the 
referred pain since the pain can still be induced after sensory loss i.e. after an 
anaesthetic block. Delayed development of referred pain and hyperalgesia provide 
evidence for central input given that sensitisation of central neurons take time to 
develop (Coderre and Katz 1997). In addition, referred pain and hyperalgesia 
spread to areas from different dermatomes, indicating a dependency on Central 
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Nervous System (CNS) changes (Coderre and Katz 1997). This central 
hyperexcitability may be responsible for the hyperalgesia, expansion of the 
receptor fields which enlarges the referred pain areas in patients with muscle pain 
and allodynia (Arendt-Nielsen et al. 1998, Graven-Nielsen and Arendt-Nielsen 
2002). Allodynia, a painful response to non-painful stimuli, is a clinical feature of 
many conditions associated with musculoskeletal pain, such as fibromyalgia 
syndrome (FMS) (Oshinsky 2006). However, it is not specific to the muscles and 
can occur as cutaneous allodynia which is commonly associated with migraines 
(Oshinsky 2006). 
 
Central hyperexcitability can be shown in patients with chronic muscle pain, 
where muscular hyperalgesia exists in a muscle with no spontaneous pain 
(Sorensen et al. 1998). In patients with FMS, hyperalgesia and referred pain are 
observed as symptoms of widespread chronic muscle pain. 
 
Although central sensitisation is associated with pain, it is not specific to the 
condition and is present in other syndromes collectively referred to as central 
sensitivity syndromes (CSS) (Yunus 2008). The central sensitivity syndromes, 
which include circulatory, nervous, digestive, urinary and reproductive systems, 
have overlapping clinical features and are bound by the common pathophysiology 
of central sensitisation (Cassisi et al. 2008, Yunus 2008). 
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There are many confounding factors which could affect the perception of pain in 
patients with chronic myalgia, thus the need to use experimental pain models. 
Experimental pain models such as hypertonic saline infusion has been shown to 
successfully produce a muscular pain model with local and referred pain and 
hyperalgesia, which are both characteristics of clinical chronic and acute muscle 
pain (Graven-Nielsen et al. 1997a, Graven-Nielsen et al. 2001, Capra and Ro 
2004). However, experimental pain models will never be able to be identical to 
the clinical condition of chronic pain conditions because of the other variables 
besides pain which have an effect on the disorder. However, isolating and treating 
one variable, pain, would improve knowledge about the peripheral and central 
mechanisms causing pain, which would aid in improved development of drugs 
and therapy for muscle pain, as well as a better understanding of the underlying 
mechanisms involved in pain transmission, transduction and perception (Graven-
Nielsen et al. 1998, Arendt-Nielsen and Sumikura 2002).  
 
1.3   Experimental muscle pain 
Experimental pain models have been used in human and animal studies to 
experimentally induce pain and analyse the responses, whether behavioural, 
psychological or physiological (Staahl and Drewes 2004). There are various types 
of experimental pain models each inducing a different kind of pain. Cutaneous 
pain can be induced via mechanical stimulation, thermal stimulation, electrical 
stimulation and chemical stimulation (Staahl and Drewes 2004). Muscle pain, the 
focus of this paper, can be induced by ischaemic stimulation, electrical 
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stimulation, mechanical stimulation, exercise and chemical stimulation. Ischaemic 
and mechanical stimulation induce pain but are non-specific as the skin and other 
deeper tissues are also activated and contribute to the perception of pain, while 
electrical stimulation activates nerve fibres directly and is not nociceptive specific 
(Staahl and Drewes 2004). Exercise and chemical stimulation are the better 
models for muscle pain since they activate specific nociceptors in the muscle 
(Staahl and Drewes 2004). 
 
1.3.1   Delayed onset muscle soreness  
Delayed onset muscle soreness (DOMS) is the most common form of sports 
injury (Cheung et al. 2003). DOMS is a sensation of pain, discomfort and loss of 
range of movement which peaks between 24-72 hours after unaccustomed, 
eccentric exercise (Armstrong 1990; Cheung 2003; Weekerody et al. 2003). 
Eccentric exercise occurs when the muscle is lengthening during a muscle 
contraction (Cheung et al. 2003). Typically there is no pain unless the area is 
touched or contracted or stretched (Weekarody et al. 2003).  
 
1.3.1.2   Mechanisms of muscle pain 
Although the underlying mechanisms of DOMS have not yet been fully 
elucidated, it has been proposed to be a result of a combination of inflammation 
and muscle damage. It is believed that the structural damage of the muscle causes 
altered muscle function, which may lead to decreased muscle strength for up to 10 
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days after the onset of DOMS (Armstrong 1990, Cheung 2003). Eccentric 
exercise can cause high tensile forces and disruptions in the cross-bridges in the 
muscle, which ultimately leads to muscle fibre damage (Cheung 2003). The 
muscle damage occurs almost immediately after eccentric exercise, but gets worse 
two or three days after exercise – this explains why the pain peaks after two or 
three days (Allen 2001). 
 
Muscle damage triggers a local inflammatory response which is divided into the 
acute phase response and the chronic phase response (Macintyre et al. 1995, 
Proske and Morgan 2001). The acute phase response occurs immediately after 
injury and is characterised by the influx of neutrophils into the injured tissue, 
whereas chronic inflammation is the phase involving the removal of neutrophils 
by macrophages and monocytes (Macintyre et al. 1995). It is evident that the 
inflammatory response occurs during exercise, since various inflammatory 
markers have been identified in eccentrically exercised muscle (Macintyre et al. 
1995). 
 
In summary, DOMS characteristically produces a muscle pain only when 
contracted stretched or touched in the area of the muscle affected i.e. hyperalgesia.  
This model would not be a suitable experimental pain model for chronic pain 
since the pain is only felt when pressure is applied, and no referred pain is 
induced. Therefore, a better model is needed to fulfil the requirements of chronic 
muscle pain. 
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1.3.2   Hypertonic saline infusion 
The “Hypertonic Saline Pain Model” was first introduced by Kellgren and Lewis 
in 1938. The model involves the infusion of hypertonic saline (HS), a 5% NaCl 
solution, which is an algogenic substance, into a muscle. It usually involves an 
infusion into only one muscle and the quality of pain induced using this model 
elicits local as well as referred pain and hyperalgesia (Graven-Nielsen and Mense 
2001). In addition to hypertonic saline producing a good model of muscle pain, 
there are other advantages to its use: namely; the pain is short-lasting with no 
reported long term side effects (Graven-Nielsen and Arendt-Nielsen 2003). . This 
model has become a popular method of inducing muscle pain since information 
on both the sensory and motor effects can be attained (Arendt-Nielsen et al. 
1997).  
 
A local pain, defined as the “pain around the injection site” is induced by 
hypertonic saline infusion (Graven-Nielsen et al. 1997b). After infusion of 
hypertonic saline in normal, healthy subjects, it has been shown that VAS scores 
increased significantly from 0 cm to a peak rating within a range of 3.6 - 7.2cm 
(Graven-Nielsen et al. 1997a; Graven-Nielsen et al. 1997b; Graven-Nielsen et al. 
1998; Johansen et al 1999; Graven-Nielsen et al. 2000; Graven-Nielsen et al. 
2003).  The increase in the pain rating has been found to be dependent on the rate, 
duration and the cumulative volume of the infusion.  
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When assessing pain using the MPQ during an infusion of hypertonic saline, the 
most frequently chosen word during the infusions, at a higher rate of pain on the 
visual analogue scale (approximately 72mm) is “cramping” (Graven-Nielsen et al. 
2003). When the peak pain on the VAS is approximately 40 – 50mm, the words 
most frequently chosen by the subjects are “taut”, “radiating”, “tight” and 
“drilling” (Graven-Nielsen et al. 1997a). Since the words selected from the MPQ 
differ with changing VAS pain ratings, it seems that there is a link between the 
pain intensity and pain quality in this model. 
 
Referred pain is also elicited by hypertonic saline infusion, and the size of the area 
of the referred pain is dependent on the intensity and duration of the infusion of 
hypertonic saline (Graven-Nielsen et al. 1998), although continuous infusion 
produces and maintains referred pain with decreasing referred pain intensity over 
time (Graven-Nielsen et al. 1997a). Referred pain appears approximately 20 
seconds after the perception of local pain (Arendt-Nielsen and Svensson 2001). 
Hypertonic saline infused into the tibialis anterior muscle, a muscle frequently 
used in hypertonic saline induced pain experiments, induces referred pain at the 
ventral part of the ankle discontinuous with the local pain area, and to the frontal 
aspect of the ankle (Graven-Nielsen et al 1997a; Graven-Nielsen et al 1998) (See 
Figure 2).  
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1.3.2.1   Mechanisms of muscle pain 
Although the hypertonic saline method has been extensively used to induce 
muscle pain, it is not fully understood how the pain is initiated (Graven-Nielsen et 
al. 1997b). Graven-Nielsen and colleagues (1997b) have suggested that 
hypertonic saline infusion into a muscle increases the intramuscular sodium 
concentration, which causes depolarization resulting in action potentials. The 
action potentials result in activation of muscle nociceptors, particularly group III 
and group IV afferents which transmit the impulse to the dorsal horn in the spinal 
cord where the information is processed (Graven-Nielsen and Arendt-Nielsen 
2002).  
 
The pain intensity following hypertonic saline is different when administering it 
as a bolus or infusing it continually.  In a study conducted by Graven-Nielsen and 
colleagues (2003), a 0.5ml/min rate of infusion over a period of 6 minutes 
produced a peak pain rating of approximately 72mm on the Visual Analogue 
Scale. This high pain rating is due to the constant infusion of saline over 6 
minutes – the cumulative volume of the saline caused a high pain rating. Four 
separate 0.5ml injections of saline given at five minute intervals produced a peak 
pain rating after the first infusion (40mm) which decreased after the subsequent 
infusions (Graven-Nielsen et al. 1997a). In this case the cumulative volume of 
hypertonic saline did not cause an increase in the pain rating because the 
interstimulus interval was too long. However, when the interstimulus interval was 
 14 
short the peak pain rating had a positive correlation to the cumulative infusion 
volume (Graven-Nielsen et al. 1997a). 
 
The “Hypertonic Saline Pain Model” of inducing pain mimics the sensation of 
muscle pain seen in patients with chronic pain. For people with chronic pain, the 
combination of pain and sleep disturbance is a double-edged sword: the sleep 
disturbance has been implicated in an exacerbation of pain perception the 
following day, and an increase in the daytime intensity of pain is presumed to 
increase the sleep disruption (Ağargün et al. 1999, Lautenbacher et al. 2005). 
Conducting research in the field of sleep and pain is very difficult since there are 
many contributing factors involved in poor sleep and pain perception: negative 
mood and depression, chronic insomnia, sleep medication effects and different 
levels of pain perceived by patients (Lavigne et al. 2004). Research shows that 
disturbances in the central nervous system is the final pathway that causes the 
non-restorative sleep syndrome (Moldofsky 1993). In order to understand how 
experimental pain may interfere with sleep some knowledge of the basic construct 
of sleep is essential. Therefore, the next part of my discussion will focus on sleep 
and how it is affected by pain.. 
 
1.4   Sleep Physiology 
One of the early misconceptions about sleep was that it is an interruption of the 
waking state and a passive and relatively unchanging process (Kleitman 1939). In 
fact, sleep is a very active state and some sleep processes involve a greater amount 
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of brain activity than during wakefulness (Hirshkowitz 2004). Sleep is an essential 
physiological process and does not take a single form - several stages of sleep 
exist, each with specific characteristics (Hirshkowitz 2004). 
 
1.4.1   Characteristics of sleep 
Polysomnography (PSG) allows for the objective assessment of sleep by 
measuring brain activity, eye activity and muscle activity (Carskadon and Dement 
2005). Three fundamental measures are used as a basis for defining the different 
stages of sleep. Brain activity is measured using electroencephalography (EEG); 
muscle tone is measured using electromyography (EMG) and eye activity is 
measured using electro-oculography (EOG).  
 
Rechtschaffen and Kales (1968) developed a sleep stage classification which 
characterises sleep into two different types; non-rapid eye movement sleep 
(NREM), and rapid eye movement sleep (REM). Non-rapid eye movement sleep 
can be further divided into four sleep stages namely; stages 1, 2, 3 and 4 
(Carskadon and Dement 2005, Rechtschaffen and Kales 1968). Wakefulness, a 
period when one is drowsy and has the eyes closed, is called stage 0 and is 
characterized by alpha waves, normally in the range of 8-11 Hz (Rechtschaffen 
and Kales 1968).  
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Stage 1 is a transition phase from wakefulness to sleep (stage 2 sleep or deeper) 
(Horne 1990). This first stage of sleep is characterized by low voltage, mixed 
frequency EEG, reduction of alpha activity and appearance of ‘vertex sharp 
waves’. There is also rolling of the eyes, which can be seen when observing the 
electro-oculogram (Hirschkowitz 2004, Rechtschaffen and Kales 1968). 
 
 Stage 2 sleep contains a mixture of theta wave activity (within a frequency range 
of 3.5-7.5 Hz), and two unusual wave phenomena. These wave phenomena, which 
occur periodically, and are defining characteristics of stage 2 sleep, are termed 
sleep spindles and K complexes. The former comprises a sudden increase in wave 
frequency, while the latter shows as a sudden increase in wave amplitude 
(Hirschkowitz 2004, Rechtschaffen and Kales 1968). 
 
Stage 3 and 4 sleep are often collectively referred to as slow wave sleep (SWS) or 
delta sleep. This stage is characterised by the presence of high amplitude, low 
frequency delta waves, which make up between 20 and 100% of the wave patterns 
during these sleep stages (Hirshkowitz 2004, Rechtschaffen and Kales 1968).  
 
REM sleep is characterised by the concomitant appearance of relatively low 
voltage, mixed frequency EEG, muscle atonia in the EMG and episodic bursts of 
rapid eye movement (Rechtschaffen and Kales 1963). Saw-tooth theta waves may 
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also be present during REM sleep (Hirshkowitz 2004, Rechtschaffen and Kales 
1963).  
 
During a normal sleep period, NREM sleep and REM sleep alternate in 3-5 
cycles, each lasting approximately 90 to 120 minutes (Hirshkowitz 2004) (Figure 
3). The pattern or progression of the sleep stages throughout a sleep period is 
referred to as sleep architecture (Spriggs 2002). In general, SWS predominates in 
the first half of the night, while REM sleep is the dominant sleep state during the 
last half of the sleep period (Carskadon and Dement 2005, Hirshkowitz 2004).  
 
Stage 1 usually comprises 2-5% of total sleep time (TST), stage 2 occupies 45-
55% of TST, SWS constitutes 13-23% of TST and REM sleep constitutes 20-25% 
of TST (Figure 4) (Hirshkowitz 2004). Patients who suffer from chronic pain do 
not follow the same patterns as people who have normal, undisturbed sleep. Their 
sleep will be comprised of frequently fragmented sleep and a decreased amount of 
REM and SWS (Drewes et al. 1997, Call-Schmidt and Richardson 2003). 
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Figure 3. Progression of sleep stages during a complete night of sleep in a  
                     normal, healthy adult (Hirschkowitz 2004) 
 
 
Figure 4. Composition of sleep in a normal healthy adult (Hirschkowitz 2004) 
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Just as the different stages of sleep are defined by their specific characteristics, 
sleep also has specific functions. 
 
1.4.2   Function of sleep 
The function of sleep is still highly debated, with various theories trying to answer 
the question, “Why do we sleep?” Sleep is a physiological process essential to 
survival and brings about a conservation of energy due to a reduced body 
temperature and metabolic rate – this energy conserving state is beneficial for 
recuperation (Peever and McGinty 2007).  
 
In addition to the previously mentioned physiological functions of sleep, it has 
been found that sleep deprivation can lead to increased infections, thus playing a 
role in immune function (Horne 1988, Peever and McGinty 2007). The clinical 
features of chronic pain conditions such as FMS, are related to altered biological 
rhythmical functions (Moldofsky 1993). Features such as altered immune function 
and serotonin metabolism are related to the disturbances in the sleep of FMS 
patients (Moldofsky 1993). Sleep is a state of healing and growth with the greatest 
amount of human growth hormone (HGH) being naturally released during the first 
three hours of sleep (typically SWS) (Horne 1988). This release of HGH is not 
dependant on time of day as it is absent in the sleep deprived (Horne 1988). A 
study conducted on FMS patients showed reduced somatomedin C, which is 
considered to be an indication of low levels of growth hormone (Bennett et al. 
1992). Approximately 80% of the daily production of growth hormone is released 
during SWS (Bennett et al. 1992). Patients with FMS have decreased SWS which 
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would account for the low levels of somatomedin C. Sleep may also be linked to 
memory consolidation and learning by maintaining neural networks and 
enhancing synaptic plasticity (Peever and McGinty 2007). 
 
It still remains unclear why we sleep, but the general view is that sleep is an 
anabolic state of growth and rejuvenation while wakefulness is catabolic. The 
anabolic state of growth of sleep is so important that it needs to be conserved by 
limiting the amount of sensory input from the environment. 
 
1.4.3   Sensory perceptions during sleep 
“...sleep erects a perceptual wall between the conscious mind and the outside 
world.” (Dement 1999) 
 
Awareness can be defined as the ability to receive and integrate all incoming 
sensory information, both from the external surroundings and from within the 
body (Evans 2003). When asleep, one is not necessarily aware of auditory, visual, 
somatosensory and pain stimuli, since all but the most relevant, threatening or 
significant sensory input should be inhibited so that the sleep can be preserved 
(Campbell 2000, Kakigi 2003). For example, when music is played loudly, one 
could sleep without being disturbed, but if one’s name is whispered, one would 
immediately awake.  
 
During sleep there is little cortical activation in response to noxious stimulation 
(Kakigi et al. 2007). Since there is little cortical activation, sleep is preserved even 
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in the presence of pain, which indicates that sleep is essential and the brain needs 
to cut itself off from the outside world. This however, does not mean that the 
sleeping brain is incapable of awakening if sensory inputs are potentially harmful. 
The conscious perception of pain is triggered by a pre-frontal cortex arousal 
response (Bastuji et al. 2007).  The perception of pain is conveyed along the 
spinoreticular and trigeminothalamic tract neurons to the thalamus and brainstem, 
which act as a gating mechanism to sort through information, allowing important 
information to get through and causing an awakening response (Lavigne et al. 
2005, Soja 2007).  
 
Research on sensory perception during sleep has suggested that the threshold 
required to induce an awakening is lower in light sleep (Stage 2), and higher 
during the deeper stages of sleep (SWS) (Bentley et al. 2003, Lavigne et al. 2000, 
Muzet 2007).  
 
The perception of pain during sleep is also dependant on the type of noxious 
stimulation applied (Lavigne et al. 2007). Thermal pain stimulations, whereby a 
thermode was applied to the skin of the leg, caused microacrousals with more 
arousals observed in stage 2 than in SWS (Bentley 2007, Lavigne et al. 2000). 
Hypertonic saline infusion, which mimics muscle pain, was more likely to cause 
awakenings than microarousals during a 26 second infusion across all sleep stages 
(Lavigne et al. 2004).    
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Awakenings and arousals are not the only effects of sensory input on sleep. More 
subtle changes to sensory input can also be seen – in vasoconstrictions and heart 
rate changes (Muzet 2007). Heart rate increases after experimental nociceptive 
stimulation, which clearly shows that the sleeper still perceives external sensory 
input even if there is no arousal response (Lavigne et al. 2001, Muzet 2007).  
 
During sleep the brain reacts to all information, whether the stimulus is 
environmental or physiological – choosing to activate an arousal response or 
simply ignoring the stimulus and preserving sleep. 
 
1.4.4   Disruptions during sleep 
Sleep can be disturbed in various ways – by a number of awakenings or arousals 
during the evenings, number of sleep stage changes and changes in the sleep 
cycle. There are many causes for sleep disturbances, most caused by external 
factors.  
 
The external factors may be non-noxious or noxious. It has been found that 
noxious stimuli are more likely to cause awakenings across all sleep stages, 
whereas non-noxious stimuli are more likely to cause microarousals. Noise is a 
non-noxious external stimulus which could result in fragmentation of sleep. 
Research has shown that noise induces awakenings, at a peak noise level of 55 dB 
and above. The awakening threshold of noise is determined by the sleep stage 
involved (Muzet 2007). The time to fall asleep can also be prolonged when noise 
levels increase to 45 dB and above (Muzet 2007). The auditory stimuli are 
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processed centrally by the cortex, so the brain can act swiftly to the signals 
(Kakigi et al 2007). This probably serves as a protective function. 
 
Chronic pain, as experienced in patients with fibromyalgia and rheumatoid 
arthritis, is a noxious stimulus, and has been associated with sleep disturbance 
(Drewes et al. 1997, Call-Schmidt and Richardson 2003). EEG measurements in 
patients with chronic musculoskeletal pain show changes in sleep in various ways 
such as: more superficial and frequently fragmented sleep, a longer sleep onset 
latency, decreased overall quality of sleep, reduction in SWS and REM sleep, and 
an increased frequency of alpha waves (also known as alpha intrusion) (Branco et 
al. 1994, Call-Schmidt et al 2003, Drewes and Arendt-Nielsen 2001, Nicassio et 
al. 2002, , Moldofsky 1993, Moldofsky 2001). 
 
Whether a stimulus is noxious or non-noxious, the sleeping brain adapts to the 
interference by conveying a response i.e. a sleep disruption (Parrino et al. 2007). 
K-complexes are brief responses typically seen during normal sleep, but can also 
appear when there are environmental interruptions (Smith and Buenaver 2007). 
Another brief response commonly occurring during sleep is microarousals, which 
has an increased frequency in the presence of non-noxious stimuli (Lavigne et al. 
2004). These brief responses to a stimulus allow for sleep continuity, unless 
further arousal is needed in response to additional incoming environmental 
information (Smith and Buenaver 2007). The longest responses are awakenings 
(Bentley 2007). The greater the need for one to be aware of a stimulus, the greater 
the degree of disruption.  
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As discussed before, many factors not related to the pain may contribute to sleep 
disturbance in chronic pain patients. Isolating and then treating one variable, pain, 
may make it easier to detect if that variable is responsible for the poor sleep. An 
experimental model, which  mimics the pain observed in patients with chronic 
pain , would assist in defining the interaction between muscle pain and sleep. 
 
1.5   Experimental pain and sleep 
Sleep disturbance is a major complaint among patients with chronic pain with 
extensive research been carried out to achieve greater insight into the relationship 
between sleep and pain (Sessle 2007).  
 
Many studies have been conducted investigating other types of pain (such as joint, 
cutaneous thermal and muscle pain) during sleep (Drewes et al. 1997, Lavigne et 
al. 2001, Bentley et al. 2003, Lavigne et al. 2004). These studies have shown that 
although the noxious stimuli produces a disruption in sleep, the degree of noxious 
stimulus required to produce the disruption observed is not always the same 
across the stimuli. Also, the studies assessed different end-points of sleep 
disruption and therefore, they are difficult to compare (Bentley 2007). 
 
1.5.1   Joint and cutaneous thermal pain 
Joint pain has been studied using a pressure device to cause pain (Drewes et al. 
1997). Such pressure applied was found to decrease the frequency of waves 
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observed in deeper stages of sleep (delta waves) and to increase frequencies of 
waves found in lighter stages of sleep (alpha and beta waves). In the same study 
the effects of cutaneous pain, using an argon laser was investigated. There was no 
significant difference found in quality of sleep between baseline results compared 
to results when cutaneous pain was induced. The researchers speculated that there 
could possibly be a mechanism ensuring continuous sleep despite cutaneous 
stimuli during sleep (Drewes et al. 1997).  
 
Studies investigating thermal pain showed that stage 2 sleep is more sensitive to 
changes than other sleep stages (Lavigne et al. 2001). A higher intensity of pain is 
also needed to cause an arousal from SWS and REM sleep when compared to 
stage 2 (Bentley 2003). 
 
1.5.2   Delayed onset muscle soreness 
In the case of pain caused by DOMS, surprisingly only one study has been 
performed assessing polysomnographic sleep changes following eccentric 
exercise (Breus et al. 2000). The main finding was that DOMS did not cause 
widespread sleep disruption i.e. only one disturbance was documented – a 
significant decrease in stage one sleep (Breus et al 2000). The data showed that 
DOMS improved sleep to some extent or had no effect at all (Breus et al 2000). 
The researchers believe that their findings are important since their results show 
that not all people suffering from pain experience sleep disturbances.  
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1.5.3   Hypertonic saline infusion 
 The hypertonic saline model has been previously used as a method to induce 
muscle pain during sleep in two separate studies. Hypertonic saline was infused, 
as at a rate of 0.5ml over 40 seconds, into the anterior tibialis muscle during SWS 
(Drewes et al. 1997). The post-injection percentage of the delta waves decreased 
while the percentage of alpha and beta waves increased which indicated that there 
was an arousal effect caused by muscle pain. The increase in the percentage of the 
alpha wave band, also known as the alpha wave anomaly, mimics that seen in 
patients with rheumatic pain (a chronic muscular pain condition (Drewes et al. 
1997, Lavigne et al. 2004).  
 
In a second study conducted by Lavigne and colleagues (2004), hypertonic saline 
was infused at a rate of 0.3ml over 26 seconds into the deltoid muscle. This 
procedure was performed 8 times throughout the sleep period. The infusion was 
performed in sleep stages 2, SWS and REM. The aim of the study was to assess 
the effect of hypertonic saline over all sleep stages using sleep arousal responses 
as a marker of sleep disruption. Their results showed that after the infusion, the 
amount of time spent in stage 2 increased while the time spent in SWS decreased, 
implying that the sleep quality was poorer. The infusion of hypertonic saline also 
evoked similar sleep awakening responses over all of the sleep stages. As useful 
as the current technique is, the study suggested that experimental pain stimuli of 
longer durations may be needed to mimic sleep findings observed in the sleep of 
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patients with chronic pain. However, hypertonic saline does cause sleep disruption 
and thus is a good model to mimic musculoskeletal pain. 
 
Unlike the muscle pain induced in the two studies using hypertonic saline 
described above, patients with chronic muscle pain do not experience sudden 
bursts of pain only lasting for 20 to 40 seconds throughout the night. The pain is 
likely to be of lower intensity but lasting for a longer period of time. Therefore, in 
order to mimic the condition more effectively, the time over which the noxious 
stimulus is applied should be increased. 
 
There are various ways of measuring how sleep is affected (Bentley 2007). 
Researchers have used EEG power spectra, heart rate response, EMG muscle 
response, microarousals, awakenings, sleep stage shifts and magnetic fields of the 
brain as end point measures of sleep disruption (Bentley 2007). However, usually 
only one or two end-point measures were assessed during each study, and not all 
of the studies involved every stage of sleep. Hence, an experimental model for 
longer duration acute pain during sleep should assess multiple end-points of sleep 
disruption during all stages of sleep. 
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1.6   Aims 
1. The aim of the study is to investigate the effect of intramuscular 
hypertonic saline infusion on sleep architecture when infused during sleep 
for a duration of ten minutes 
2. To assess whether the end-points of sleep disruption is constant over 
subjects 
3. To assess whether the type of sleep disruption is dependent on stage of 
sleep involved 
 
Study hypothesis: If all possible responses/end-points are assessed, then multiple 
responses will be observed depending on the time and individuality of subjects. 
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Chapter 2 
 
Materials and Methods 
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2.1   Subject Recruitment 
Twelve healthy males between the ages of 19 and 29 years from a university 
student population volunteered to participate in the study. Ethical clearance was 
obtained from the University of the Witwatersrand’s Committee for Research on 
Human Subjects, which adheres to the principles of the Declaration of Helsinki 
(Clearance no. M060408). All subjects gave written informed consent before 
participation. The study was conducted at the Wits Dial-a-Bed Sleep Laboratory. 
 
All volunteers presented with regular sleep-wake cycles and showed no signs of 
psychological disorders. The Pittsburg Sleep Quality Index (PSQI) (Appendix A) 
was used to screen for any sleep disorders (Buysee at al. 1989). A global PSQI 
score greater than 5 was taken to indicate poor sleep quality.  
 
The 30-item version of the General Health Questionnaire (GHQ) (Appendix B) 
was used for psychological and general health screening. A score of less than 6 
was used to indicate a normal psychological status (Goldberg 1972). 
 
During the study subjects were advised to continue with their normal daily 
activities. Subjects were requested not to consume any form of alcohol during the 
study period and no coffee or tea in the evenings. Subjects were also asked not to 
smoke from 6pm on the day when sleep recordings were made. The restrictions 
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were made due to the fact that smoking and changes in caffeine can affect the 
integrity of sleep. 
 
2.2   Nociceptive Stimulus 
On arrival at the sleep laboratory, an anaesthetic cream, Emla ™ (lignocaine 2.5% 
and prilocaine 2.5% Astrazeneca Pharmaceuticals, South Africa), was used to 
anaesthetize the area of the skin where the catheter was to be inserted. An hour 
after application of the anaesthetic cream, an indwelling 22 gauge, 25mm catheter 
was inserted into the tibialis anterior muscle by a medical doctor. The needle was 
inserted into the muscle at a distance of 120mm below the patella to a depth of 
about 20 mm (Graven-Nielsen 1997a). The catheter was attached to a 20ml 
syringe loaded with either 5% sterile hypertonic saline or 0.9% sterile isotonic 
saline. The loaded syringe was then placed in an infusion pump, which controlled 
the infusion of the saline at a rate of 0.3ml/min, for a period of 10 minutes. During 
sleep, the infusion either lasted for a period of 10 minutes, or until a full arousal 
was noticed. After full arousal the infusion was stopped and the subject was left to 
go back to sleep to continue the experiment. 
 
2.3   Experimental Protocol 
Each subject was required to undergo one adaptation and two experimental nights 
in the Wits Sleep Laboratory. During the second and third sessions, either 
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hypertonic or isotonic saline infusions were given during sleep in random order. 
The experiment was double-blind. 
 
2.3.1   Adaptation Night 
The first of the three nights was the adaptation night. The purpose of the 
adaptation night was to familiarize the subjects with all of the experimental 
procedures as well as sleeping in the environment of the sleep laboratory. The 
adaptation night always took place two to five nights before the first recording 
night. 
 
Subjects arrived at the sleep lab at least two hours before bed-time. Bed-time was 
determined by the participant. Immediately after arrival, the catheter was inserted 
as described in section 2.2 and subjects received one infusion of both hypertonic 
and isotonic saline at 0.3ml/min for 10 minutes whilst awake. The order of the 
infusions was randomized, and infusions were administered at least 10 minutes 
apart to allow for the pain to subside.  If the pain had not completely disappeared 
after the ten minutes, the second infusion was delayed until the subject was 
completely pain free. 
 
During the infusion subjects scored their pain on two different scales: 
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1) A 100mm Visual Analogue Scale (VAS), where the anchor at 0mm 
represented “no pain” and the anchor at 100mm represented “worst pain 
ever felt”, was used to assess the intensity of the pain. The VAS was given 
to the subject every 30 seconds throughout the infusion, and the subject 
marked on the line the point which they felt best represented their pain. 
2) A McGill Pain Questionnaire (MPQ) (Appendix C) was used to assess the 
quality of pain. Subjects were then asked to complete the MPQ once the 
infusion had stopped. 
 
The subjects were then prepared for overnight polysomnography which included: 
electroencephalography (EEG), electro-oculography (EOG), and 
electromyography (EMG). Recordings were made on a computerized EEG system 
(Easy EEG version 2.0.2, Cadwell Laboratories Inc, Kennewick WA). The 
placement of the electrodes on each subject’s head and face was identical to that 
of the successive recording nights. Electrodes were placed on the scalp at C3 and 
C4 sites, according to the international 10/20 system, and were cross-referenced to 
A1 or A2. To record muscle activity (EMG), two electrodes were placed over the 
submentalis muscle, and eye movements (EOG) were recorded by placing 
electrodes next to each eye. Both EOG electrodes were placed approximately 1cm 
from the outer corner of the eye; one approximately 1cm up from the middle of 
the eye, and the other approximately 1cm down from the middle of the eye 
(Rechtschaffen and Kales 1968). One ground electrode was placed on the 
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forehead. All electrodes were filled with conducting paste and secured with 
micropore tape. 
 
No actual polysomnographic recordings were made on the adaptation night. The 
purpose therefore, of the preparation for overnight polysomnography on the 
adaptation night, was merely to get the subjects accustomed to sleeping with the 
electrodes attached to their head and face. Subjects went to bed at their usual 
bedtimes, slept through the night in a sound-attenuated bedroom with no further 
nociceptive input applied.  
 
In the morning, subjects were asked to fill out the Morning Questionnaire to 
assess the preceding night’s sleep (Appendix D). A repeat 10 minute infusion 
during wakefulness was done after waking with a repeat VAS and McGill Pain 
Questionnaire, identical to that described above. 
 
2.3.2   Experimental Nights 
For the two experimental nights the subjects had the catheter inserted, syringes 
loaded and the sleep recording electrodes attached as in the adaptation night. No 
infusions during wakefulness were performed.  
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The order of isotonic and hypertonic infusions was randomized and subjects were 
not informed as to which solution was going to be infused during the night (only 
one solution was infused during each night). The infusions commenced once the 
subject was asleep and had spent at least two minutes in a specific sleep stage. 
The infusions were run during three sleep stages (stage two, SWS and REM) and 
at least 15 minutes elapsed between each infusion. The time interval between 
infusions was given so that one infusion would not impact on subsequent 
infusions. Not more than six infusions took place during any particular night. 
Once the subject was asleep and had been in either stage two, SWS and REM 
sleep for a minimum of two minutes, the infusion of hypertonic saline or isotonic 
saline was initiated.  
 
The study was concluded when all the subjects had completed both trials, with 
both isotonic and hypertonic saline on separate occasions, thus, each subject acted 
as his own control. 
 
Following each experimental night, subjects were asked to fill out the Morning 
Questionnaire. In addition they were asked if they remembered receiving noxious 
stimuli during the night. To assess for hyperalgesia, a repeat 10 minute infusion 
during wakefulness was done after waking with a repeat VAS and McGill Pain 
Questionnaire, identical to that described in 2.3.1. The morning infusion was 
performed with the same solution as the previous evenings’ infusions.  
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The following sleep variables were considered endpoints in the study: 1) micro-
arousals, 2) awakenings, 3) sleep stage shifts and. These variables are defined as 
follows: 
 
1) Micro-arousal: the sleep of the subject is stable for at least 1 minute before 
the stimulus, after which an abrupt shift in the EEG waves lasting between 
3 and 10 seconds is observed. (American Sleep Disorders Association, 
American Academy of Sleep Medicine) 
 
2) Full arousal: scored for responses lasting more than 10 seconds (American 
Sleep Disorders Association) 
 
 
3) Sleep stage shifts: scored when sleep stage changes from a deeper to a 
lighter stage of sleep (such as in an increased frequency of alpha waves) 
(American Sleep Disorders Association). 
 
The presence of each variable was noted as well as time since the start of the 
infusion. If multiple events occurred, the type and time delay for each subsequent 
event was noted and called second and third responses. A minimum of 10 
continuous seconds of intervening sleep was necessary to score a second arousal. 
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A frequency shift had to be three seconds or greater in duration to be scored an 
arousal. 
 
2.4   Statistical Analysis 
All data were analysed using the Instat statistical package (GraphPad Software 
Inc., version 3, 1997). A two-tailed probability of P< 0.05 was considered to be 
statistically significant. All parametric values are expressed as mean  SD, while 
all non-parametric values are expressed as medians (lower, upper 95% confidence 
limits). 
 
All VAS measurements (in mm), used to describe both pain and sleep 
subjectively, were normalized before statistical analysis using the arcsine 
transformation. However, in the results (text and graphs) all the VAS data are 
reported as back transformed values. 
   
The area under the curve for the VAS-time curve was analysed using the Students 
T-test and One-way ANOVA to test for the differences between the hypertonic 
saline and isotonic saline infusions, and to compare the three hypertonic saline 
infusions. The area under the curve is a statistical means of summarizing 
information from a series of measurements across time on one individual. 
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The Friedman Statistic Test will be used to test for differences between the 
evening and morning infusion data (the pain rating index (PRI) and number of 
words chosen in the MPQ).  
 
The percentage of responses during sleep was analysed using the The Chi-Square 
Test Statistic. T-tests were used to evaluate differences in the time to a response. 
The remaining sleep data was analysed using descriptive statistics. 
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3.   Results 
3.1   Subject characteristics 
The age range of the subjects was between the ages of 19 and 29 years (mean 
22.2, SD ± 3.1). The mean score for the PSQI was 2.82 ± 0.91, and the mean 
score for the GHQ was 3.35 ± 1.0, with both values being within the normal 
range. 
 
3.2   Awake Data 
3.2.1   Pain Intensity 
The area under the curve for the VAS pain scores obtained during the hypertonic 
saline infusion and isotonic saline infusion for the adaptation night, adaptation 
morning and experimental morning were calculated. All hypertonic saline 
infusions were significantly more painful than the isotonic saline infusions on the 
adaptation night (p<0.0001, t=6.174), the adaptation morning (p<0.0001, t=6.625) 
and the experimental morning (p<0.0001, t=7.282) (figure 5). No significant 
difference was found between the infusions of hypertonic saline at either the 
adaptation night, adaptation morning or experimental morning (p=0.5437, 
F(1.09)=0.6265). 
 
The pain induced by the hypertonic saline becomes significantly different at 150 
seconds compared to baseline (30seconds) on the adaptation night (p < 0.01, 
n=12, F=7.701), on the adaptation morning (p<0.01, n=12, F=7.255) and on the 
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experimental morning (p<0.01, n=12, F=12.27). The pain then remained 
significantly higher than baseline for the rest of the infusion, indicating a 7½ 
minute long painful experience (Figure 6).  
 
No significant difference was found in the median PRI (Pain Rating Index) and 
number of words chosen when comparing the hypertonic saline infusions at the 
end of the infusion on the adaptation night (PRI 19, words 8), the adaptation 
morning (PRI 19, words 9) and the experimental morning (PRI 17, words 8) 
(p=0.8255 for PRI, p=0.8769 for words).  
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Figure 5: Bar graph of area under curve for visual analogue scale pain scores 
during hypertonic and isotonic saline infusions. *p<0.0001 
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3.2.2   Pain Quality 
 
Table 1: Words from the McGill Pain Questionnaire used to describe pain after 
hypertonic saline infusions 
Adaptation night Adaptation morning  Experimental morning 
Pricking (67%) 
Tight (50%) 
Itching (42%) 
Sore (42%) 
Numb (42%) 
Itching (42%) 
Tight (42%) 
Sharp (42%) 
Sore (67%) 
 43
0 30 60 90 120 150 180 210 240 270 300 330 360 390 420 450 480 510 540 570 600
-10
0
10
20
30
40
50
60
  *
Time (s)
Va
s 
Sc
or
e 
(m
m
)
 
Figure 6: Median VAS-time curve after infusion of hypertonic saline and isotonic saline over ten minutes during wakefulness 
(▼=hypertonic saline infusion on experimental morning, ■=hypertonic saline infusion on the adaptation night, ▲=hypertonic saline 
infusion on the adaptation morning, ●=isotonic saline infusion on the experimental morning, □=isotonic saline on the adaptation 
night, X=isotonic saline on the adaptation morning). * p<0.01 
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3.3.   Sleep Data 
3.3.1   Isotonic saline infusions 
During all sleep stages, only two subjects had responses to the isotonic saline 
infusions. The subjects both had microarousals as a response, and only during 
stage 2 (figure 7). 
 
3.3.2   Hypertonic saline infusions (refer to table 2)    
Stage 2 
During stage 2, nine subjects received one infusion, while three subjects received 
more than one infusion. Subjects received more than one infusion when their 
sleep remained stable enough to do more infusions during that particular sleep 
stage. Ten of the subjects had full arousals as a first response. The mean time for 
first responses during stage 2 was 182.1 seconds (SD ± 129.6). All responses to 
the infusions are indicated in Table 2. 
 
 Of the subjects who had first responses, other than full arousals as their first 
response, four had second responses. The mean time between the first and second 
response, irrespective of the type of response was 47 seconds (SD ± 30.73). The 
second and third responses to the infusions are indicated in Table 2.  
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SWS  
During SWS, 11 subjects received one infusion, while one subject was given more 
than one infusion. Of these infusions, four had a full arousal and four had a sleep 
stage shift as a first response. The mean time for first responses during SWS was 
174.5 seconds (SD ± 133.8). All responses to the infusions are indicated in Table 
2. 
 
Of the subjects who had first responses, other than full arousals as their first 
response, seven had second responses. The mean time between the first and 
second response, irrespective of the type of response was 86.4 seconds (SD ± 
57.78). One subject had a full arousal 55 seconds after the second response. The 
second and third responses to the infusions are indicated in Table 2. 
 
REM 
During REM sleep, six subjects had one infusion, and the other six subjects had 
more than one infusion. Of these infusions, seven had a full arousal as a first 
response. The mean time for first responses during REM sleep was 163.1 seconds 
(SD ± 107.2). All responses to the infusions are indicated in Table 2. 
 
Of the subjects who had first responses, but did not have full arousals as their first 
response, eight had second responses. The mean time between the first and second 
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responses, irrespective of the type of response was 88 seconds (SD ± 54.6). One 
subject had a full arousal during REM sleep, 370 seconds after the second 
response. The second and third responses to the infusions are indicated in Table 2. 
 
3.3.3   Time to responses 
The first time a response occurred, regardless of what type of response or which 
sleep stage it occurred in, was at a mean time of 172.2 seconds (SD ± 119.1). The 
corresponding VAS score was at approximately 32-42mm (read off graph from 
figure 6). The second time a response occurred was at a mean time of 230 seconds 
(SD ± 111.7). The corresponding VAS score was at approximately 39-45mm 
(read off graph from figure 6). A significant difference was found between the 
time of the third responses and the time of the first and second responses 
(p=0.0004, t=3.824 and p=0.0079, t=2.909). There was no significant difference 
between the time of the first responses and the time of the second responses 
(p=0.0623, t=1.897). 
 
The time to responses, irrespective of whether the responses are first, second or 
third, are as follows: microarousals: mean 189.6 seconds, SD ± 162.4; sleep stage 
shifts: mean 210 seconds, SD ± 162.9; and full arousals: mean 173.7, SD ± 85.71. 
There was no significant difference in time between the responses (p=0.8900, 
F=0.2086). When comparing the different sleep stages, no significant difference 
was found in the time in which the responses occurred (p=0.6141, F=0.4913). 
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3.3.4   Validity of responses 
Within a subject there is no validity in the type of response. Only two subjects 
were consistent in that they had full arousals only across all stages. There is also 
no consistent response in subjects who had multiple infusions during a stage of 
sleep. However, there seems to be a trend within each stage. 
 
3.3.5   Subjective morning assessment 
None of the subjects reported poor sleep quality the morning after the hypertonic 
saline trial night (figure 8). All subjects were able to differentiate whether they 
had received isotonic or hypertonic saline infusions the following morning. 
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Isotonic saline
Hypertonic saline
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Figure 7: Percentage of subjects with microarousals (MA), sleep stage shifts (SSS) and full arousals (FA) following 
isotonic and hypertonic saline over all stages. *p<0.05, **p<0.01, ***p<0.001 between isotonic and hypertonic saline 
infusions 
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Table 2:  Responses and variability within and between subjects observed during 
Stage 2, SWS and REM sleep to hypertonic saline infusions. Fa – full arousal; sss 
– sleep stage shift; ma – microarousal. The responses to multiple infusions are 
indicated on separate lines. Commas (,) distinguish between first, second and third 
responses.  
Subject Stage2 SWS REM 
1 fa sss, ma  ma, fa 
fa 
2 ma, fa 
sss, fa 
fa 
ma, fa 
fa 
ma 
3 fa 
fa 
No response ma 
4 fa No response fa 
5 fa fa fa 
ma, fa 
fa 
6 fa sss, fa ma 
7 ma, fa fa fa 
fa 
8 ma, fa sss, fa ma, fa 
fa 
9 fa fa fa 
ma, fa 
10 ma sss, fa fa 
11 No response sss, ma ma, sss 
12 fa fa fa 
sss 
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Figure 8: Subjective morning assessment of sleep quality from visual analogue 
scales for the hypertonic saline and isotonic saline experimental nights 
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We successfully induced muscle pain in the tibialis anterior muscle after infusion 
of hypertonic saline. The subjects muscle soreness was identified by an increased 
subjective pain score, as measured by the VAS and PRI. The area under the curve 
for all three hypertonic saline infusions were significantly greater than their 
corresponding isotonic saline infusions indicating that hypertonic saline causes 
pain. The intensity of pain increased significantly until maximum pain had been 
reached, plateaued between 330 and 480 seconds then slowly began to decrease 
and did not change in intensity once maximum pain had been reached. This 
decrease is similar to findings of Zhang and colleagues (1993), who applied a 
continuous infusion of hypertonic saline, and to that of the study by Graven-
Nielsen and colleagues (1997b), where they showed a decrease in pain with 
subsequent infusions (of 20 seconds) of hypertonic saline.  
 
Future studies could use our results as a base for testing changes in pain during a 
chronic infusion of hypertonic saline and increase the time of infusion to 20 or 30 
minutes in order to ascertain whether the pain continues to decrease after ten 
minutes. 
 
The lack of a significant difference in VAS scores or PRI or number of words 
between three hypertonic saline infusions performed on different days and at 
different times showed both a lack of circadian rhythm and a lack of hyperalgesia 
after the experimental night, establishing that all the data is valid. The type of pain 
was also uniform across all hypertonic saline infusions since the words used to 
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describe the pain were similar. Even though the words chosen from the MPQ were 
different from the words used to describe the muscle pain in the tibialis anterior in 
previous studies (Graven-Nielsen et al. 1997a, Graven-Nielsen et al. 1997b, 
Graven-Nielsen et al. 1998, Graven-Nielsen et al. 2003), most of the words 
chosen were from same word groups.  The reason for this could be a result of 
differing volumes and rates changing the severity of pain, therefore influencing 
the type word chosen.  
 
Our study has shown that hypertonic saline can be safely infused during sleep, 
with no adverse effects, such as prolonged muscle pain. The muscle pain induced 
by the hypertonic saline caused a disturbance in all sleep stages. The time at 
which the disturbances occurred during the different sleep stages was not 
significant, indicating that the reactions to the stimuli are independent of the sleep 
stage involved i.e. no matter what stage is affected, a reaction will occur. When 
comparing the time at which the disturbances occurred during sleep and the time 
at which a peak pain was felt during the awake infusions, the result is that the 
disturbance appears at a much lower corresponding VAS score.  This indicates 
that pain is perceived at a low threshold during sleep. The difference in pain 
perception during sleep and when awake could be due to the fact that a sleeping 
brain needs to become aware of a painful stimulus and thus needs to allow 
information to get through at a lower level to ensure safety and survival. An 
awake brain, however, is already aware of the environment and is required to react 
at a much higher level of pain.  
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Patients with rheumatic diseases such as fibromyalgia and rheumatoid arthritis 
usually complain of decreased sleep quality, which can be seen in the specific 
changes in the macrostructure and microstructure of their sleep. These 
disturbances have been shown to be significant in the appearance of the symptoms 
of these conditions, and have been assessed in four different kinds of experiments 
(Moldofsky and MacFarlane 2001). 
 
The first type of experiment evaluates sleep disturbances in patients who are 
diagnosed with FMS. The studies showed a poor quality of sleep with longer sleep 
latencies, decreased sleep efficiency, frequently fragmented sleep, reduction in 
SWS and REM sleep and an increased incidence of alpha EEG during NREM 
sleep (Branco et al. 1994, Call-Schmidt and Richardson 2003, Drewes and 
Arendt-Nielsen 2001, Nicassio et al. 2002, Mahowald et al. 1989, Moldofsky 
1993, Moldofsky 2001, Moldofsky and MacFarlane 2005).  
 
 The second type of experiment used to show the importance of sleep disturbances 
on symptoms of pain utilizes noise to disrupt SWS in healthy subjects (Older et al. 
1998, Lentz et al. 1999). These experiments artificially induced diffuse muscle 
and fatigue similar to the symptoms indicating a link between SWS disruption and 
pain symptoms.  
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Sleep deprivation studies are also used to show the correlation between sleep 
disturbance and pain. In a study conducted by Onen and colleagues (2001), 40 
hours of sleep deprivation showed a reduction in pain thresholds. The pain 
threshold was restored to its normal value after SWS had fully recovered. 
 
The experimental pain model of using hypertonic saline to mimic the pain felt by 
patients with chronic muscle pain is often used during sleep to observe various 
disturbances. Previous studies using the method have produced an acute pain 
during sleep resulting in an increased percentage of alpha and decreased SWS 
(Drewes et al. 1997, Lavigne et al. 2004). Our study used a longer duration acting 
model to generate more changes in the sleep macrostructure and succeeded in 
disturbing sleep across all stages. The most common response to an infusion of 
hypertonic saline in all sleep stages was a full arousal. Previous research has 
shown that hypertonic saline was more likely to cause full arousals than 
microarousals across all sleep stages (Lavigne et al. 2005). In the study conducted 
by Lavigne and colleagues (2005), the percentage of sleep-evoked microarousals 
and full arousals following hypertonic saline was 0% and 40%, 0% and 26.7%, 
and 0% and 45.8% for stage 2, SWS, and REM sleep, respectively. Our study, 
however, showed that microarousals did occur during all sleep stages. This 
discrepancy could be due to the methodology. A bolus infusion was given in the 
previous study, whereas a longer duration infusion was given during our study 
allowing other sleep disturbances to be observed.  
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The type of disturbance/arousal observed while infusing hypertonic saline during 
sleep was dependant on the sleep stage involved, i.e. the infusion affected the 
sleep stages differently. During stage two, full arousals were significantly more 
prevalent than any other sleep disturbance. In addition to full arousals, sleep stage 
shifts were significantly more common than microarousals during SWS, while 
microarousals were significantly more prevalent during REM. Our data suggest 
that the threshold for pain increases from stage two to SWS, and from SWS to 
REM, which is similar to the findings in previous studies (Lavigne et al. 2000, 
Bentley et al. 2003). This fits in with the basic physiology of sleep where: stage 
two is the lightest stage of sleep, SWS being a deeper form of sleep and REM 
being the deepest.  
 
Previous studies assessing the relationship between sleep and pain have not 
assessed all sleep disturbances as an end-point measure, and did not apply the 
infusions beyond one minute. A study conducted by Drewes and colleagues in 
1997, observed the effect of hypertonic saline infusion, argon laser and joint 
pressure on sleep microstructure. The study was only performed during SWS and 
the infusions lasted 40 seconds, joint pressure was applied for 10 seconds and the 
laser was transmitted to the skin for a maximum of 45 seconds. The results 
showed a decrease in delta waves with no changes observed during cutaneous 
pain (Drewes et al. 1997). 
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Two thermal studies tested the effect of increasing temperatures on the different 
stages of sleep with a full arousal being the end-point measure (Lavigne et al. 
2000, Bentley et al. 2003). Both studies concluded that the subject is more 
sensitive to pain during stage 2 than during SWS or REM sleep (Lavigne et al. 
2000, Bentley et al. 2003). 
 
Only one study looked at microarousals, awakenings, and sleep stage shifts as 
end-point measures. The study observed changes induced by hypertonic saline in 
all stages of sleep, but the infusions only lasted 26 seconds at a time (Lavigne et 
al. 2004). They found that there were more awakenings than microarousals – 
similar to our findings (Lavigne et al. 2004). 
 
Our study showed that in order to get a more accurate understanding of what kind 
of changes occur during each sleep stage, all possibilities of sleep disturbances 
and arousals need to be observed. The pain stimulus should also be long enough 
to see an effect – our data showed that responses occurred at around three 
minutes, a time which was not included in previous studies. 
 
The number of responses and the sequence of responses following hypertonic 
saline infusions showed no trend and is completely dependent on the individual. 
These results may help explain some of the conflicting results obtained in 
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previous experimental pain studies especially where their percentage of responses 
were analysed. 
 
When asked to score their sleep quality on a 100mm scale, subjects reported no 
significant difference in the time to fall asleep, the number of awakenings, sleep 
quality and morning alertness between the isotonic and the hypertonic trial. 
However, all subjects remembered receiving a painful stimulus during the night. 
Despite having sleep disturbances throughout the night, the subjects perceived 
their sleep quality to be normal since they had their normal hours of sleep. It 
would have been interesting to do an afternoon study on the subjects to assess 
their daytime sleepiness. This information could have helped to evaluate whether 
the sleep disturbances affected their sleep quality and daytime alertness. 
 
A limitation of the study is that not all subjects had more than one infusion in a 
particular stage of sleep during the night, thus it was difficult to establish whether 
there were any trends within or across individuals. Future studies could build on 
from our experience and include the method of doing a minimum of 3 infusions 
per sleep stage. Further input would be to assess the beginning of the evening’s 
stage two sleep separately from stage two at the end of the evening as it is 
possible that the brain responds differently to stimuli during the same stage at 
various parts of the evening. A second limitation of the study is that the time at 
which a sleep arousal occurred was compared to the time at which it corresponded 
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to the pain intensity during wakefulness. Such direct comparison needs further 
validation. 
 
Our study showed that experimental pain will eventually result in a full arousal, 
depending on how intense the pain gets. Mild pain causes other sleep disruptions 
like microarousals and sleep stage shifts to occur before the full arousal can take 
place, depending on the sleep stage involved.  However, not all subjects have the 
same sleep disruptions. Consequently, if a sleep study is performed with the aim 
of observing one sleep disruption, one might not even find the disruption in any 
given subject. Therefore, future sleep studies need to assess multiple sleep 
disturbances across all sleep stages. 
 
In conclusion, we have successfully developed a longer duration acute model for 
muscle pain during sleep using a ten minute infusion of hypertonic saline. The 
data suggests that pain during sleep, if continued for an extended period, may 
trigger multiple sleep disturbances during sleep and the specific effects may be 
determined by the individual variation and by the sleep stage involved. The sleep 
disturbances found in our model of experimental pain may be similar to those 
found in patients with chronic muscle pain and may also explain differing results 
between previous experimental pain and sleep studies. These significant findings 
need to be further assessed with more infusions during the evening and daytime 
function and reaction tests during the day. 
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APPENDIX A 
 
PITTSBURGH SLEEP QUALITY INDEX (PSQI) 
Name: ___________________    ID No: _______________________ 
Date: _______________________     Age: _____________________ 
 
Instructions: 
The following questions relate to your usual sleep habits during the past month 
only. Your answers should indicate the most accurate reply for the majority of 
days and nights in the past month. Please answer all questions. 
1.    During the past month, when have you usually gone to bed at night? 
                                 USUAL BED TIME ____________________ 
2.    During the past month, how long (in minutes) has it taken you to fall asleep 
each night? 
                                             NUMBER OF MINUTES ________________ 
3.    During the past month, when have you usually gotten up in the morning? 
                                              USUAL WAKE UP TIME_________________ 
4.    During the past month, how many hours of actual sleep did you get at night?  
       (This may be different from the number of hours you spend in bed)   
                                               HOURS OF SLEEP PER NIGHT____________ 
 
For each of the remaining questions, check one response that fits best. Please 
answer all questions. 
 
5. During the past month, how often have you had trouble sleeping because you 
a) Cannot get to sleep within 30 minutes 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
b) Wake up in the middle of the night 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
c) Have to get up to use the bathroom 
Not during the  
 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
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d) Cannot breathe comfortably 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
e) Cough or snore 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
f) Feel too cold 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
g) Feel too hot 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
h) Had bad dreams 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
i) Have pain 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
j) Other reason(s), please describe: 
___________________________________________________________
___________________________________________________________ 
How often during the past month have you had trouble sleeping because 
of this? 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
6.    During the past month, how would you rate your sleep quality overall? 
Very good Fairly good Fairly bad Very bad 
 
 
7.    During the past month, how often have you taken medicine (prescribed or     
       ‘over-the- counter’) to help you sleep? 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
 
 78 
8.   During the past month, how often have you had trouble staying awake while     
      driving, eating meals, or engaging in social activity? 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
9.    During the past month, how much of a problem has it been for you to keep up  
       enough enthusiasm to get things done? 
No problem at 
all 
Only a slight 
problem 
Somewhat of a 
problem 
A very big 
problem 
 
10.    Do you have a bed partner or roommate? 
No bed partner 
or roommate 
Partner/roommate 
in other room 
Partner in 
same room, but 
not same bed 
Partner in 
same bed 
  
If you have a roommate or bed partner, ask him/her how often in the past month 
you have had... 
a) Loud snoring 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
b) Long pauses between breaths while asleep 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
c) Legs twitching or jerking while asleep 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
 
d) Episodes of disorientation or confusion during sleep 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
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e) Other restlessness while you sleep; please describe: 
___________________________________________________________
___________________________________________________________ 
Not during the 
past month 
Less than once a 
week 
Once or twice a 
week 
Three or more 
times a week 
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APPENDIX B 
 
GENERAL HEALTH QUESTIONNAIRE 
Please read carefully: 
We would like to know if you have any medical complaints, and how your health 
has been in general over the last few weeks. Please answer ALL the questions on 
the following pages simply by underlining the answer that you think most applies 
to you. Remember that we want to know about present and recent complaints, not 
those that you had in the past. 
It is important that you try and answer ALL 30 questions. 
Thank you very much for your co-operation. 
HAVE YOU RECENTLY: 
1 Been able to 
concentrate on 
whatever you’re 
doing? 
Better than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
2 Lost much sleep over 
worry? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
3 Been having restless, 
disturbed nights? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
4 Been managing to 
keep yourself busy 
and occupied? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
5 Been getting out of the 
house as much as 
usual? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
6 Been managing as 
well as most people 
would in your shoes? 
Better than 
most 
Same as 
usual 
Less than 
most 
Much less 
than usual 
7 Felt on the whole you 
were doing things 
well? 
Better than 
most 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
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8 Been satisfied with the 
way you’ve carried 
out your tasks? 
Most satisfied Same as 
usual 
Less 
satisfied 
than usual 
Much less 
than usual 
9 Been able to feel 
warmth and affection 
for those close to you? 
Better than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
10 Been finding it easy to 
get on with other 
people? 
Better than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
11 Spent much time 
chatting with friends? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
12 Felt that you are 
playing a useful part in 
things? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
13 Felt capable of making 
decisions about 
things? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
14 Felt constantly under 
strain? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
15 Felt you couldn’t 
overcome your 
difficulties? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
16 Been finding life a 
struggle all the time? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
17 Been able to enjoy 
your normal day-today 
activities? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
18 Been taking things 
hard? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
19 Been getting scared or 
panicky for no good 
reason? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
20 Been able to face up to 
your problems? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
21 Found everything 
getting too much for 
you? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
22 Been feeling unhappy Not at all No more Rather more Much more 
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and depressed? than usual than usual than usual 
23 Been losing 
confidence in 
yourself? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
24 Been thinking of 
yourself as a worthless 
person? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
25 Felt that life is entirely 
hopeless? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
26 Been feeling hopeful 
about your own 
future? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
27 Been feeling 
reasonably happy, all 
things considered? 
More than 
usual 
Same as 
usual 
Less than 
usual 
Much less 
than usual 
28 Been feeling nervous 
and strung-up all the 
time? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
29 Felt that life isn’t 
worth living? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
30 Felt at times you 
couldn’t do anything 
because your nerves 
were too bad? 
Not at all No more 
than usual 
Rather more 
than usual 
Much more 
than usual 
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APPENDIX C 
 
McGILL PAIN QUESTIONNAIRE 
SUBJECT CODE: _______________      DATE: ________________     TIME: _______________ 
PRI: S _________ A _________ E ________ M ________ PRI (Total) _________ PPI _________ 
             (1-10)                    (11-15)               (16)                   (17-20)                                    (1-20) 
 
1 2 3 4 
1. Flickering 
2. Quivering 
3. Pulsing 
4. Throbbing 
5. Beating 
6. Pounding 
1. Jumping 
2. Flashing 
3. Shooting 
1. Pricking 
2. Boring 
3. Drilling 
4. Stabbing 
5. Lancinating 
1. Sharp 
2. Cutting 
3. Lacerating 
 
5 6 7 8 
1. Pinching 
2. Pressing 
3. Gnawing 
4. Cramping 
5. Crushing 
1. Tugging 
2. Pulling 
3. Wrenching 
1. Hot 
2. Burning 
3. Scalding 
4. Searing 
1. Tingling 
2. Itching 
3. Smarting 
4. Stinging 
 
9 10 11 12 
1. Dull 
2. Sore 
3. Hurting 
4. Aching 
5. Heavy 
1. Tender 
2. Taut 
3. Rasping 
4. Splitting 
1. Tiring 
2. Exhausting 
1. Sickening 
2 Suffocating 
 
13 14 15 16 
1. Fearful 
2. Frightful 
3. Terrifying 
1. Punishing 
2. Gruelling 
3. Cruel 
4. Vicious 
5. Killing 
1. Wretched 
2. Blinding 
1. Annoying 
2. Troublesome 
3. Miserable 
4. Intense 
5. Unbearable 
 
17 18 19 20 
1. Spreading 
2. Radiating 
3. Penetrating 
4. Piercing 
1. Tight 
2. Numb 
3. Drawing 
4. Squeezing 
1. Cool 
2. Cold 
3. Freezing 
1. Nagging 
2. Nauseating 
3. Agonising 
4. Dreadful 
5. Torturing 
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APPENDIX D 
 
WITS DIAL.A.BED SLEEP LABORATORY 
MORNING FORM 
DATE: _____________________                  CODE: _______________________ 
TITLE OF STUDY: _________________________________________________ 
 
What time did you switch off the light to go to sleep last night? _______________ 
How long do you think it took you to fall asleep last night? __________________ 
How many times did you wake up last night? _____________________________ 
If you did wake up during the night, how long were you awake for? ___________ 
Do you remember having a dream last night? _____________________________ 
What time did you wake up this morning? _______________________________ 
Do you remember having any pain last night? _____________________________ 
 
On the scales below, please make a mark to indicate how your night was different, 
if at all, from your usual sleep at home. 
 
Time to fall asleep 
 
 
 
Number of times woken up 
 
 
 
The shortest it 
has ever been 
The longest it 
has ever been 
Much more 
than normal 
Much less than 
normal 
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Sleep Quality 
 
 
 
Morning Alertness 
 
 
Worst possible Best ever 
Awfully sleepy 
and tired 
Marvellously 
alert and 
energetic 
